TLPH · Talphera, Inc.
Substantial doubt about the company's ability to continue as a going concern.
“The Company has incurred recurring operating losses and negative cash flows from operating activities since inception and expects to continue to incur operating losses and negative cash flows in the future. These conditions raise substantial doubt about the Company's ability to continue as a going concern.”View the 10-Q filed Aug 12, 2026
Price & Indicators
Up next
Metrics snapshot
Useful current figures from the complete screener profile.
AI Brief
Q2 FY26 earnings call · Aug 12, 2026TL;DR. Talphera reported Q2 2026 results with the NEPHRO CRRT registrational study of nafamostat at 75% enrollment and on track for completion this year; the KDIGO 2026 draft guideline added nafamostat as an acceptable CRRT regional anticoagulant, and updated market research raised the projected U.S. CRRT opportunity to ~200,000 annual procedures (up 21%) for a potential 2027 launch.
- + Updated market research raised projected U.S. CRRT procedures in 2027 to ~200,000, a 21% increase
- + Management believes existing cash plus ~$16M of conditional financing tranches is sufficient through potential 2027 PMA approval
- + Company regained Nasdaq compliance with the $1 bid price rule
AI-generated from the earnings call and 8-K · may contain errors · not investment advice
Equibles Rating
blended score · not investment adviceBlended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Guidance & track record
Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.
Technicals
trend & momentum for long-term holders NeutralIllustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
Earlier KPI extraction records exist, but do not meet the current evidence-completeness requirements. No current verified series is available. Earlier figures remain withheld until revalidated; this is not evidence that the company reports no KPIs.
Versus peers
Drug Manufacturers - Specialty & Generic — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
TLPH
this stock
Talphera, Inc.
|
$61.25M | -2.6% | -73.1% | — | 1.3% |
|
TAK
Takeda Pharmaceutical Co Ltd
|
$60.23B | +16.1% | — | — | 0.1% |
|
GALDY
Galderma Group AG/ADR
|
$46.00B | -6.7% | — | — | 0.0% |
|
TEVA
Teva Pharmaceutical Industries Ltd
|
$45.67B | +25.4% | +4.3% | 64.3 | 2.7% |
|
HLN
Haleon plc
|
$40.72B | -12.3% | — | — | 0.5% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionPerformance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| TLPH | -5.1% | -6.7% | +33.7% | -4.3% | -2.6% |
| SPY | +2.0% | +1.7% | +11.3% | +2.2% | +14.3% |
| vs SPY | -7.1% | -8.4% | +22.4% | -6.5% | -16.9% |